Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    

ASCO Conference Sheds Light on Colon Cancer Treatment


Colorectal cancer is the third most common cancer diagnosed in both men and women in the United States (skin cancer aside). The American Cancer Society anticipates 95,270 new cases of colon cancer in 2016 and more than 49,000 deaths from the disease.

Fortunately, death rates tied to colon cancer are actually on the decline thanks to increased awareness, earlier screenings and advances in medical therapies. Those breakthroughs were highlighted during the annual American Society of Clinical Oncology (ASCO) conference in June. Oncologist Johanna Bendell, MD, director of the GI Cancer Research Program and associate director of the Drug Development Program at Sarah Cannon Research Institute, said findings presented at ASCO would be a game changer for oncologists and colon cancer patients.


The most promising news in the treatment of colon cancer revolves around immunotherapy, or using the body's own system to attack cancer. Bendell said patients with microsatellite instable metastatic colon cancer could derive the greatest benefit from immunotherapy.

What is Microsatellite Instability?

MSI is a change that occurs in the DNA of certain cells, such as tumor cells, in which the number of repeats of microsatellites (short, repeated sequences of DNA) is different than the number of repeats that was in the DNA when it was inherited. According to the National Cancer Institute, the cause of microsatellite instability may be a defect in the ability to repair mistakes made when DNA is copied in the cell.

Approximately 15 percent of MSI patients also have hereditary nonpolyposis colorectal cancer (HNPCC), or Lynch Syndrome. HNPCC is a genetic condition that can encourage growth of additional cancers through the GI tract, making treatment even more critical for the MSI population. Bendell said 25-50 percent of MSI patients studied have shown an incredible response to immunotherapy. While patients with MSI represent only five percent of overall metastatic colorectal cancer cases, Bendell urges gastroenterologists to test all cancer patients for MSI. "In my practice that's the first question I ask," she said.

Non-MSI Patients

What about the 95 percent of patients without microsatellite instability?

During the June ASCO conference, Bendell and her colleagues presented data on the use of MEK inhibitory drugs, already approved by the FDA for treatment of melanoma. When used in non-MSI patients, the drug can increase T-cell production and essentially rev up the immune system, triggering a similar response as MSI patients to immunotherapy.

Twenty percent of non-MSI patients who received a combination of MEK inhibitors and immunotherapy responded to treatment. That means a 20-30 percent response rate to immunotherapy across the colon cancer population.

"The next big question in drug development is, 'How can we make more people respond to immunotherapy?'" said Bendell, who's been involved in the trial for two years. "Our presentation was just the beginning of the wave examining this treatment."

Next generation immunotherapy trials are now underway to examine the use of other agents in combination with immunotherapy. The data is so promising that a randomized study has begun for FDA approval, with the first trial sites already opening.

Left or Right?

Doctors have long known that patients with left-sided metastatic colon cancers live longer than those with right-sided, and now researchers are beginning to learn why. "We used to think it was because we caught them earlier because they become symptomatic sooner, but now we see there are biologic distinctions between tumors on the left and right sides," said Bendell, who noted that patients with left-sided colon cancer often live 15 months longer than those with right-sided.

Typically, right-sided colon cancers carry the BRAF mutation and have hyper-methylation, which carries a poor prognosis. Recent microbiology studies also show different bacteria present in left and right sides can affect the molecular profile of the area of the colon where the bacteria live.

"We think that bacteria has a role in a tumor's molecular profile, and data presented from a large study of chemo using two different target agents has led to a discussion of the optimal first line treatment for colon cancer," Bendell explained. "We saw that for patients with right-sided colon cancer they did not appear to benefit at all from the use of a certain treatment. Should we use one chemo agent over another depending on the side affected?"

What Providers Can Do

While researchers await that answer, Bendell encouraged providers to note each patient's micro stability status, BRAF status, expanded RAS testing, and the side of colon affected, as every piece of information could prove helpful for future treatment. She also encouraged primary care providers to take an aggressive approach in monitoring and examining patients of all ages with persistent GI symptoms, as doctors are seeing a rise in the development of colon cancers among the younger patient population.

"This is all super exciting news in the treatment of colon cancer and is setting the stage for how research in colon cancer will keep moving forward," Bendell said of recent advances.



Heading: CRITICS Study Changing Protocol for Gastric Cancer Treatment

Less common than colon cancer, stomach cancer will be diagnosed in 26,000 individuals in 2016. Findings from CRITICS - an international, multicenter, randomized, phase III study that examined the necessity of radiation along with chemotherapy for gastric cancers - was also presented at ASCO.

"CRITICS was big news in that we haven't really known how to best treat patients who've had stomach cancer removed by surgery," explained Bendell. "We didn't know if patients needed radiation as well as chemo to improve survival."

The result? "We don't need radiation therapy to treat gastric cancers," she said.

More often than not, the benefit of radiation was to 'clean up' after inadequate resections during gastric surgery. That's why Bendell emphasized the need for patients with gastric cancers to seek treatment in a specialty facility with experience in performing these surgeries. This can reduce the risk of adverse events from the surgery and help ensure the correct surgery is performed, eliminating the need for radiation.

"There's plenty of data that correlates outcomes with the surgeon's experience," she said. "When you do the right surgery, you don't need radiation. This changes the standard of care for gastric cancer patients."



Sarah Cannon

Dr. Johanna Bendell

Related Articles:

Recent Articles

Cancer Care on the Cutting Edge

Nashville physician-scientists are helping lead the way in advancing cancer care.

Read More

The Evolution of Senior Living

The senior living industry is undergoing a makeover as baby boomers shift focus from medical-directed care to hospitality-driven services.

Read More

When Basic Science Becomes a Breakthrough

Noted immunologists joined forces at the recent International Cancer Immunotherapy Conference to discuss the importance of fostering and funding basic science.

Read More

Dr. Meredith McKean Brings New Hope, More Options for Melanoma Patients

Oncologist Meredith McKean, MD, MPH, overseeing Sarah Cannon's Melanoma Research Program

Read More

ONcology Rounds

News of note in cancer research, treatment and partnerships.

Read More

Ascension Saint Thomas Opens Cancer Center

Ascension Saint Thomas recently celebrated the grand opening of their comprehensive new cancer center on the Midtown campus.

Read More

NMGMA 10 Minute Takeaway

Medicare Part B representative from Palmetto GBA offered updates and resources to navigate compliance.

Read More

Improving Quality, Lowering Cost of Care for Seniors

Five years into the Medicare Shared Savings Program, more and more ACOs are beginning to demonstrate the ability to improve quality while lowering costs.

Read More

Planning Ahead: Patients & Power of Attorney

The time to think about a durable power of attorney is long before it's needed. Barbara Moss discusses the importance of the document in healthcare.

Read More

Council on Aging Honors Middle Tennesseans

The Council on Aging (COA) of Middle Tennessee hosted their 27th Annual Sage Awards on Oct. 29. With a belief that aging should be celebrated and embraced and that older adults have a lifetime of wisdom and experience to offer communities, the Sage Awards are presented each year to older adults who have made outstanding contributions to Middle Tennessee.

Read More

Email Print



2016 ASCO Conference, Colon cancer, CRITICS study, GI Cancer Research Program at Sarah Cannon Research Institute, immunotherapy, Johanna Bendell, MEK inhibitors and colon cancer
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: